[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-356626-105":59,"doc-detail-356626-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","plasminogen-activator-inhibitor-1-mediates-tolerance-to-antipd-1-immunotherapy-in-nonsmall-cell-lung-cancer","Plasminogen Activator Inhibitor-1 Mediates Tolerance to Anti–PD-1 Immunotherapy in Non–Small Cell Lung Cancer","","Immune checkpoint inhibitors (ICI) improve outcomes in non-small cell lung cancer (NSCLC), yet cure rates remain limited because tolerant persister cancer cells can survive during treatment. This study investigates whether plasminogen activator inhibitor-1 (PAI-1) drives tolerance to anti–PD-1 therapy and whether PAI-1 inhibition can overcome it. Using a mouse subcutaneous tumor model, surviving cells after anti–PD-1 defined aPD-1 antibody–tolerant persisters show elevated PAI-1, mesenchymal programs, PD-L1, macrophage presence, and angiogenesis. Combined anti–PD-1 with the PAI-1 inhibitor TM5614 reduced these features, increased tumor-infiltrating lymphocytes, and prolonged tumor growth inhibition, implicating PAI-1 in survival via EMT and tumor microenvironment remodeling.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/plasminogen-activator-inhibitor-1-mediates-tolerance-to-antipd-1-immunotherapy-in-nonsmall-cell-lung-cancer/356626/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/plasminogen-activator-inhibitor-1-mediates-tolerance-to-antipd-1-immunotherapy-in-nonsmall-cell-lung-cancer/356626.png","ImageObject",300,407,{"name":92,"@type":93},"WPS_1786070896","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-09","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":44},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What problem does the study address in NSCLC treatment with anti–PD-1?","Question",{"text":112,"@type":113},"It addresses the low cure rate caused by tolerant persister cancer cells that survive during ICI therapy, enabling disease progression.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How were anti–PD-1-tolerant persister cells identified in the study?",{"text":117,"@type":113},"In a mouse subcutaneous tumor model, cancer cells surviving within the tumor 7 days after anti–PD-1 antibody treatment were defined as aPD-1 antibody–tolerant persister cells (aPD-1-TP).",{"name":119,"@type":110,"acceptedAnswer":120},"What effect did combining an anti–PD-1 antibody with the PAI-1 inhibitor TM5614 have?",{"text":121,"@type":113},"The combination decreased mesenchymal gene expression, PD-L1 expression, tumor-associated macrophages, and angiogenesis, while increasing tumor-infiltrating lymphocyte counts and prolonging inhibition of tumor growth.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},356626,1790366808,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":44,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},549768072016,"https://ap-avatar.wpscdn.com/davatar_155a257f0dc6eb9ab79c44ca47cae57d","Plasminogen Activator Inhibitor-1 Mediates Tolerance to Anti–PD-1 Immunotherapy in Non–Small Cell Lung Cancer  \nMasahiko Sumii1, Takeshi Masuda2, Kiyofumi Shimoji2, Kakuhiro Yamaguchi2, Shinjiro Sakamoto2, Yasushi Horimasu2, Takahiro Mimae3, Taku Nakashima1, Hiroshi Iwamoto1, Yoshihiro Miyata3, Hironobu Hamada4, Morihito Okada3, Toshio Miyata5, and Noboru Hattori1  \n|  |  | A |  | B | S |  | T | R |  | A |  | C | T |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |\n| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |\n|  | Immune checkpoint inhibitors (ICI) have improved the prognosis of patients with non–small cell lung cancer (NSCLC), but the cure rate remains low because tolerant persister cancer cells can survive within the tumor during ICI treatment. We have previously reported that plasminogen activator inhibitor-1 (PAI-1) is involved in tolerance acquisition to osimertinib in EGFR-mutated NSCLC. This study aimed to examine the role of PAI-1 in ICI tolerance and whether PAI-1 may be a therapeutic target to overcome this tolerance. In a mouse subcutaneous tumor model using Lewis lung carcinoma or KLN205 cells, cancer cells surviving within the tumor 7 days after anti–PD-1 (aPD-1) antibody treatment were defined as aPD-1 antibody–tolerant persister cells (aPD-1-TP). PAI-1 and mesenchymal gene expression levels were higher in aPD-1-TPs than in control cells. IHC analyses\u003Cbr>􀀶 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | showed higher numbers of tumor-associated macrophages, expression of PD-L1 in cancer cells, and degree of angiogenesis. In contrast, the number of tumor-infiltrating lymphocytes was lower in aPD-1 antibody–tolerant tumors than in control tumors. Combination treatment with an aPD-1 antibody and the PAI-1 inhibitor, TM5614 decreased mesenchymal gene expression, PD-L1 expression, tumor-associated macrophage numbers, and angiogenesis and increased tumor-infiltrating lymphocyte counts intolerant tumors. Furthermore, it resulted in prolonged inhibition of tumor growth. In conclusion, this study underscores the involvement of PAI-1 in the survival of aPD-1-TPs via epithelial– mesenchymal transition and alteration of the tumor microenvironment. Combination treatment with an aPD-1 antibody and TM5614 can be a new therapeutic strategy for NSCLC. |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |\n\nIntroduction  \nLung cancer is the leading cause of cancer-related deaths worldwide (1), and its incidence is still expected to increase in the future (2) . Lung cancer is histopathologically classified into small cell lung cancer and non–small cell lung cancer (NSCLC), with NSCLC accounting for 85% of cases. For approximately half of patients with advanced NSCLC without targetable driver mutations who cannot undergo curative surgery or radiotherapy, the standard first-line treatment is cytotoxic chemotherapy combined with immunotherapy using immune checkpoint inhibitors (ICI) that target PD-L1 or PD-1 . However, only a small proportion of patients are cured, and more than half experience ","cbCaieqc8Qs1KT1A","https://ap.wps.com/l/cbCaieqc8Qs1KT1A","pdf",39632692,13,"English","# Introduction\n## Immune checkpoint inhibitors and limited cure rates\n## Progression mechanisms and tumor-immune microenvironment\n## EMT and drug-tolerant persister cells","[{\"question\":\"What problem does the study address in NSCLC treatment with anti–PD-1?\",\"answer\":\"It addresses the low cure rate caused by tolerant persister cancer cells that survive during ICI therapy, enabling disease progression.\"},{\"question\":\"How were anti–PD-1-tolerant persister cells identified in the study?\",\"answer\":\"In a mouse subcutaneous tumor model, cancer cells surviving within the tumor 7 days after anti–PD-1 antibody treatment were defined as aPD-1 antibody–tolerant persister cells (aPD-1-TP).\"},{\"question\":\"What effect did combining an anti–PD-1 antibody with the PAI-1 inhibitor TM5614 have?\",\"answer\":\"The combination decreased mesenchymal gene expression, PD-L1 expression, tumor-associated macrophages, and angiogenesis, while increasing tumor-infiltrating lymphocyte counts and prolonging inhibition of tumor growth.\"}]","Plasminogen Activator Inhibitor-1 Mediates Tolerance to Anti–PD-1 Immunotherapy in Non–Small Cell Lung Cancer | PDF",1790126393,33,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/de10a7df09b912c30bde6dd743b9bb94.webp",983,1315,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/3ea479b6eba1856cc30ce32a28de4127.webp",982,1314,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/dd197dd6feb46772a29b39f344591c63.webp",981,1312,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/70faef7e619d514fc2580e5d267dc745.webp",980,1311]